You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Patent: 8,258,098

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,258,098

Title:	Antitumoral treatments
Abstract:	The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.
Inventor(s):	Faircloth; Glynn Thomas (Cambridge, MA), Aviles Marin; Pablo Manuel (Madrid, ES), LePage; Doreen (Cambridge, MA), Izquierdo; Jesus San Miguel (Salamanca, ES), Pandiella; Atanasio (Salamanca, ES)
Assignee:	Pharma Mar, S.A. (Madrid, ES)
Application Number:	12/278,559
Patent Claims:	see list of patent claims

Details for Patent 8,258,098

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26	Start Trial	Pharma Mar, S.A. (Madrid, ES)	2039-03-29	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	002	1997-11-26	Start Trial	Pharma Mar, S.A. (Madrid, ES)	2039-03-29	RX		search
Genentech Inc	RITUXAN HYCELA	rituximab; hyaluronidase (human recombinant)	SOLUTION;SUBCUTANEOUS	761064	001	2017-06-22	Start Trial	Pharma Mar, S.A. (Madrid, ES)	2039-03-29	RX	Orphan	search
Genentech Inc	RITUXAN HYCELA	rituximab; hyaluronidase (human recombinant)	SOLUTION;SUBCUTANEOUS	761064	002	2017-06-22	Start Trial	Pharma Mar, S.A. (Madrid, ES)	2039-03-29	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 8,258,098

Subscribe to access the full database, or Start Trial
Country	Patent Number	Publication Date
Australia	2007220050	Aug 29, 2013
Australia	2007220050	Sep 07, 2007
Canada	2643238	May 03, 2016
Canada	2643238	Sep 07, 2007
China	101389347	Mar 18, 2009
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Colorcon

McKesson

AstraZeneca

Express Scripts

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.